This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Agilent officials believe that the comprehensive asset-management programs that it and a couple of key competitors have launched over the past couple of years are winning over a cost-conscious pharmaceutical industry, and will eventually be used by a growing number of large and mid-tier firms.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.